The predictive value of ERG protein expression for development of castration‐resistant prostate cancer in hormone‐naïve advanced prostate cancer treated with primary androgen deprivation therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|75|14|1499-1509

ISSN： 0270-4137

Source： THE PROSTATE, Vol.75, Iss.14, 2015-10, pp. : 1499-1509

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 9, 2015-06 ,pp. : 897-906

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

By  

Urologia Internationalis, Vol. 88, Iss. 1, 2011-12 ,pp. : 25-33

Karger

Access to resources Recommend Favorite

STAMPEDE‐ing towards androgen biosynthesis inhibition for treatment of high‐risk hormone‐naïve prostate cancer: changing the LATITUDE

By  

BJU INTERNATIONAL, Vol. 121, Iss. 1, 2018-01 ,pp. : 9-11

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metabolic syndrome in castration‐resistant prostate cancer patients treated with abiraterone

By  

THE PROSTATE, Vol. 75, Iss. 12, 2015-07 ,pp. : 1329-1338

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cabazitaxel for the therapy of metastatic castration‐resistant prostate cancer in the aftermath of the CHAARTED trial

By  

BJU INTERNATIONAL, Vol. 116, Iss. 6, 2015-12 ,pp. : 839-840

John Wiley & Sons Inc

Access to resources Recommend Favorite